Is IBRX or LKFT more profitable?

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Is LKFT or PRAX more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Praxis Precision Medicines N/A -43.02% -40.22%

Is LKFT or PCVX more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Vaxcyte N/A -32.51% -29.51%

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

$28.30 0.00 (0.00%)

As of 06/18/2026 04:00 PM Eastern

Compare

LKFT vs. IBRX, PRAX, PCVX, TGTX, and PTGX

Should you buy Lakefront Biotherapeutics American Depositary Shares stock or one of its competitors? MarketBeat compares Lakefront Biotherapeutics American Depositary Shares with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lakefront Biotherapeutics American Depositary Shares include ImmunityBio (IBRX), Praxis Precision Medicines (PRAX), Vaxcyte (PCVX), TG Therapeutics (TGTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Lakefront Biotherapeutics American Depositary Shares compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

ImmunityBio has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than ImmunityBio. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	68.04	-$351.40M	-$0.85	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.48	$363.05M	-$1.41	N/A

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than ImmunityBio. MarketBeat recorded 2 mentions for Lakefront Biotherapeutics American Depositary Shares and 1 mentions for ImmunityBio. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.58 beat ImmunityBio's score of 0.21 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 92.93%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $36.50, suggesting a potential upside of 28.98%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Summary

Lakefront Biotherapeutics American Depositary Shares beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Praxis Precision Medicines?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $36.50, suggesting a potential upside of 28.98%. Praxis Precision Medicines has a consensus price target of $566.21, suggesting a potential upside of 100.56%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.48	$363.05M	-$1.41	N/A
Praxis Precision Medicines	$8.55M	920.56	-$303.27M	-$13.37	N/A

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 4 mentions for Praxis Precision Medicines and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.58 beat Praxis Precision Medicines' score of 0.00 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market.

Summary

Praxis Precision Medicines beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Vaxcyte?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Vaxcyte had 14 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 16 mentions for Vaxcyte and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Vaxcyte's average media sentiment score of 0.61 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.58 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $36.50, suggesting a potential upside of 28.98%. Vaxcyte has a consensus target price of $86.00, suggesting a potential upside of 67.19%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Vaxcyte	N/A	-32.51%	-29.51%

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Vaxcyte. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.48	$363.05M	-$1.41	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

Summary

Vaxcyte beats Lakefront Biotherapeutics American Depositary Shares on 9 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to TG Therapeutics?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, TG Therapeutics had 5 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 7 mentions for TG Therapeutics and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. TG Therapeutics' average media sentiment score of 0.64 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.58 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 65.95% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has lower revenue, but higher earnings than Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.48	$363.05M	-$1.41	N/A
TG Therapeutics	$616.29M	13.22	$447.18M	$2.86	18.61

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $36.50, suggesting a potential upside of 28.98%. TG Therapeutics has a consensus price target of $52.50, suggesting a potential downside of 1.35%. Given Lakefront Biotherapeutics American Depositary Shares' higher possible upside, equities analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

TG Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 14 of the 16 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Protagonist Therapeutics currently has a consensus target price of $115.21, suggesting a potential upside of 2.09%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $36.50, suggesting a potential upside of 28.98%. Given Lakefront Biotherapeutics American Depositary Shares' higher possible upside, analysts clearly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Protagonist Therapeutics has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	157.71	-$130.15M	-$1.81	N/A
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.48	$363.05M	-$1.41	N/A

In the previous week, Protagonist Therapeutics had 9 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 11 mentions for Protagonist Therapeutics and 2 mentions for Lakefront Biotherapeutics American Depositary Shares. Protagonist Therapeutics' average media sentiment score of 1.00 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.58 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Protagonist Therapeutics and Lakefront Biotherapeutics American Depositary Shares tied by winning 8 of the 16 factors compared between the two stocks.

Get Lakefront Biotherapeutics American Depositary Shares News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LKFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LKFT vs. The Competition

Export

Metric	Lakefront Biotherapeutics American Depositary Shares	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.86B	$3.38B	$6.39B	$12.59B
Dividend Yield	N/A	2.31%	2.68%	5.68%
P/E Ratio	-20.07	19.73	24.54	24.44
Price / Sales	1.48	317.46	574.69	128.57
Price / Cash	39.07	127.04	44.20	55.21
Price / Book	0.59	8.16	10.83	6.58
Net Income	$363.05M	$23.89M	$3.57B	$337.17M
7 Day Performance	-2.08%	2.52%	0.71%	0.61%
1 Month Performance	6.35%	5.96%	3.97%	5.02%
1 Year Performance	0.28%	53.47%	28.50%	35.50%

Lakefront Biotherapeutics American Depositary Shares Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LKFT Lakefront Biotherapeutics American Depositary Shares	2.1193 of 5 stars	$28.30 flat	$36.50 +29.0%	+0.3%	$1.86B	$1.26B	N/A	1,310	News Coverage
IBRX ImmunityBio	3.1117 of 5 stars	$7.04 -1.8%	$14.20 +101.6%	+159.2%	$7.37B	$113.29M	N/A	590	Gap Down
PRAX Praxis Precision Medicines	2.2749 of 5 stars	$247.98 -2.1%	$572.72 +131.0%	+557.0%	$6.91B	$8.55M	N/A	110	Analyst Upgrade
PCVX Vaxcyte	2.6838 of 5 stars	$46.30 -0.1%	$86.00 +85.7%	+54.0%	$6.69B	N/A	N/A	160	News Coverage Insider Trade
TGTX TG Therapeutics	1.9566 of 5 stars	$41.90 +2.3%	$52.50 +25.3%	+51.3%	$6.42B	$616.29M	14.66	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LKFT) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. IBRX, PRAX, PCVX, TGTX, and PTGX

How does Lakefront Biotherapeutics American Depositary Shares compare to ImmunityBio?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Praxis Precision Medicines?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Vaxcyte?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to TG Therapeutics?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

LKFT vs. IBRX, PRAX, PCVX, TGTX, and PTGX

How does Lakefront Biotherapeutics American Depositary Shares compare to ImmunityBio?

Which has more risk and volatility, IBRX or LKFT?

Which has higher earnings and valuation, IBRX or LKFT?

Does the media prefer IBRX or LKFT?

Do analysts rate IBRX or LKFT?

Do institutionals & insiders hold more shares of IBRX or LKFT?

Is IBRX or LKFT more profitable?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Praxis Precision Medicines?

Do analysts recommend LKFT or PRAX?

Which has preferable earnings & valuation, LKFT or PRAX?

Does the media favor LKFT or PRAX?

Do institutionals & insiders hold more shares of LKFT or PRAX?

Is LKFT or PRAX more profitable?

Which has more volatility & risk, LKFT or PRAX?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Vaxcyte?

Do insiders & institutionals hold more shares of LKFT or PCVX?

Does the media refer more to LKFT or PCVX?

Do analysts recommend LKFT or PCVX?

Which has more risk and volatility, LKFT or PCVX?

Is LKFT or PCVX more profitable?

Which has better valuation & earnings, LKFT or PCVX?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to TG Therapeutics?

Do institutionals & insiders hold more shares of LKFT or TGTX?

Does the media favor LKFT or TGTX?

Is LKFT or TGTX more profitable?

Which has higher valuation & earnings, LKFT or TGTX?

Which has more volatility and risk, LKFT or TGTX?

Do analysts rate LKFT or TGTX?

Summary

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Is PTGX or LKFT more profitable?

Do analysts rate PTGX or LKFT?

Do institutionals and insiders have more ownership in PTGX or LKFT?

Which has more volatility & risk, PTGX or LKFT?

Which has better earnings and valuation, PTGX or LKFT?

Does the media prefer PTGX or LKFT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT vs. The Competition

Lakefront Biotherapeutics American Depositary Shares Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools